Literature DB >> 12149540

Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis.

J S Parmar1, T Howell, J Kelly, D Bilton.   

Abstract

The case history is presented of a patient with cystic fibrosis in whom the treatment of allergic bronchopulmonary aspergillosis with itraconazole produced an initial response but was complicated by profound adrenal shutdown and impairment of inhaled steroid clearance resulting in paradoxical Cushing's syndrome. The authors conclude that, while it is laudable to attempt to reduce the steroid burden in any patient, it is imperative that due vigilance is exercised when using a combination of agents which interact. If such a combination therapy is embarked upon, regular assessment of the pituitary adrenal axis is advisable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149540      PMCID: PMC1746400          DOI: 10.1136/thorax.57.8.749

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  12 in total

1.  Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?

Authors:  Kris De Boeck; Frans De Baets; Anne Malfroot; Kristine Desager; Françoise Mouchet; Marijke Proesmans
Journal:  Eur J Pediatr       Date:  2006-06-24       Impact factor: 3.183

2.  Cushing's syndrome without excess cortisol.

Authors:  D R Woods; C S Arun; P A Corris; P Perros
Journal:  BMJ       Date:  2006-02-25

3.  Drug interactions between inhaled corticosteroids and enzymatic inhibitors.

Authors:  Amélie Daveluy; Cécile Raignoux; Ghada Miremont-Salamé; Pierre-Olivier Girodet; Nicholas Moore; Françoise Haramburu; Mathieu Molimard
Journal:  Eur J Clin Pharmacol       Date:  2009-04-28       Impact factor: 2.953

Review 4.  The role of allergy in severe asthma.

Authors:  J L Kennedy; P W Heymann; T A E Platts-Mills
Journal:  Clin Exp Allergy       Date:  2012-05       Impact factor: 5.018

5.  Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide.

Authors:  Elke De Wachter; Jesse Vanbesien; Iris De Schutter; Anne Malfroot; Jean De Schepper
Journal:  Eur J Pediatr       Date:  2003-04-26       Impact factor: 3.183

Review 6.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

Review 7.  Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis.

Authors:  Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

Review 8.  The role of inhaled corticosteroids in the management of cystic fibrosis.

Authors:  Kristie R Ross; James F Chmiel; Michael W Konstan
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 9.  Emerging therapies for severe asthma.

Authors:  Neil C Thomson; Rekha Chaudhuri; Mark Spears
Journal:  BMC Med       Date:  2011-09-06       Impact factor: 8.775

10.  Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series.

Authors:  Rachel A Brown; Fatima Barbar-Smiley; Cagri Yildirim-Toruner; Monica I Ardura; Stacy P Ardoin; Shoghik Akoghlanian
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-07       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.